Genmab | GEN - Assets


Genmab reported DKK12.87B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Almirall EUR 2.34B 29.21M Dec/2025
Amarin USD 645.76M 25.01M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
argenx SE USD 8.68B 1.51B Dec/2025
AstraZeneca USD 114.02B 59M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Demant DKK 39.07B 6.43B Dec/2025
Exelixis USD 2.59B 250.83M Mar/2026
Fresenius Medical Care EUR 31.47B 465.26M Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
GN Store Nord DKK 28.56B 671M Mar/2026
GRIFOLS EUR 20.08B 366M Mar/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Insmed USD 2.08B 188.7M Mar/2026
Lakefront Biotherapeutics EUR 3.37B 34.09M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 51.53B 600M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
UCB EUR 18.16B 971M Dec/2025